Clinical Trial

A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2026 (before its estimated June 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the pharmacokinetic profile and safety of a single subcutaneous injection of HDM1005 solution in participants with impaired kidney function compared to healthy participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-23.
Trial Details
NCT Number NCT07559240
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions Overweight, Obese
Enrollment 30 participants
Start Date 2026-05-15
Primary Completion 2026-06-12 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08